KLAC — KLA Corporation

Sentiment as of 2026-09-13 is genuinely split. Sell-side is bullish: consensus rating of Buy with 28 buys / 14 holds / 2 sells out of 44 ratings, consensus price target $225.50 and a recent-30-day average target of $243.79 (high $325, low $180) - all well above the $180.64 print. The tape disagrees: the stock is -2.67% over one week, -13.26% over one month and -29.03% over three months, sitting 1.73% below its SMA20 (~$183.8) and 8.98% below its SMA50 (~$198.5) with RSI at 44.8 - not oversold, just drifting lower. The offset is that it is still +27.34% over six months and above its SMA200 (~$172.9), and a 10-for-1 split landed on 2026-06-11, widening the shareholder base. Net: analysts are still underwriting the AI-driven process-control ramp, while the marginal buyer has been de-rating the multiple and taking profits after a parabolic move toward $307.

Revenue has risen for ten straight quarters, from $2.397B in the Sep-2023 quarter (Q1 FY24) to $3.658B in the Jun-2026 quarter (Q4 FY26). The growth path is not linear: YoY revenue growth peaked at +30.0% in the Mar-2025 quarter, decelerated to +7.2% in the Dec-2025 quarter, then re-accelerated to +11.5% (Mar-2026) and +15.2% (Jun-2026). Sequential growth tells the same story - +2.7%, +3.6%, +7.1% over the last three quarters - i.e. an inflection, not a fade. Fiscal-year math: FY24 $9.81B -> FY25 $12.16B (+24.0%) -> FY26 $13.58B (+11.7%), so the headline annual growth rate actually halved in FY26 even as the exit quarter strengthened. Margins are the higher-quality part of the story: gross margin has been pinned at 61-62% for eight quarters, while operating margin expanded from ~37.5% in the Sep-2023 quarter to 42.5% in the Jun-2026 quarter (op income $1.554B on $3.658B revenue), with TTM operating margin at 41.7% and ROIC at 35.6%. Diluted EPS went from $0.428 (Dec-2023 quarter) to $1.040 (Jun-2026 quarter), with TTM EPS of $3.665 and TTM net income of $4.83B. The one blemish is cash conversion: TTM free cash flow was $3.767B versus $3.744B a year earlier - essentially flat (+0.6%) despite +12% revenue - because the Mar-2026 quarter FCF collapsed to $622M from $1.262B in the Dec-2025 quarter on a working-capital swing tied to the build against a >$12B backlog. Guidance for Q1 FY2027 of $4.0B revenue (+/- $200M) and $1.16 non-GAAP EPS (+/- $0.10) implies +24.6% YoY revenue growth, which would be the fastest quarter in six. Verdict: accelerating, and the acceleration is recent enough that the FY26 annual average understates it.

Expensive on trailing numbers, merely full on forward numbers. As of 2026-09-13 at $180.64: TTM P/E of 49.0x versus a 5-year average TTM P/E of 37.3x; P/S of 17.4x versus a 5-year average of 12.4x; P/B of 37.3x; PEG of 2.42; dividend yield of 0.41%; FCF yield of just 1.6% ($3.77B TTM FCF on a $236B cap); EV/EBITDA of ~42x. On forward numbers it looks much more ordinary: consensus FY2027 EPS of $5.488 gives a forward P/E of 32.9x, and my own more conservative FY2027 EPS of ~$5.20 gives 34.7x. So the entire valuation debate reduces to whether FY2027 EPS really lands near $5.00-5.50. The deterministic score's valuation context labels this 'Rich vs. its own history' (reference score 5.3), and that is fair on trailing metrics - but note the stock has already de-rated 41% from $307.37, so the market has been doing part of the work.

This is a 'priced for the ramp, tape demanding proof' situation. FY2026 actual revenue growth was +11.7%, not the low-20s the narrative implies, yet the stock still carried a 49x trailing multiple into the summer. That gap is why it fell 29% in three months: the market stopped paying for hope and started marking down the earnings multiple while it waits for the guided acceleration to appear. Q1 FY2027 guidance of $4.0B (+24.6% YoY) is the proof point - if it prints at or above the midpoint on ~43% operating margin, the TTM P/E mechanically compresses toward the high-30s and the path to the $225-245 analyst targets reopens. If it misses, or if the FY2027 revenue consensus of $18.1B (which implies +33% on a $13.58B FY26 base and is well above the Q1 guidance run-rate) gets marked down, a 49x trailing / 1.6% FCF-yield stock has a lot of air underneath it. Note also that consensus FY2027 EPS of $5.488 requires roughly a 46% operating margin on ~$18B revenue - my own bottom-up math lands closer to $5.00-5.20 - so the estimates themselves are a source of downside risk, not just the multiple.

As of 2026-09-13, RSI(14) was 44.8 - neutral, neither oversold nor overbought, which means no capitulation signal to buy. Price was 1.73% below the SMA20 (~$183.8), 8.98% below the SMA50 (~$198.5), and 4.46% above the SMA200 (~$172.9). That combination - below the short and intermediate averages but above the long-term one - is a corrective pullback inside a still-intact uptrend, not a breakdown. But momentum is clearly negative in the near term (-2.67% 1wk, -13.26% 1mo, -29.03% 3mo) against a strongly positive 6-month return of +27.34%, which tells you this whipsawed violently through the summer (roughly $141.9 six months ago, $254.5 three months ago, peak $307.37, now $180.64). Entry-timing implication: the SMA200 near $173 is the line that matters; holding it keeps the structure constructive and gives a defined risk point, while a reclaim of the SMA50 near $198 would be the first genuine trend-repair signal. Buying here is buying a falling knife with no oversold cushion - waiting for the late-October earnings print and one higher low is the lower-regret path.

• AI infrastructure capex: hyperscaler and leading-edge foundry/logic spending is the dominant demand driver, and rising chip complexity directly increases process-control intensity - KLA is a structural share gainer here.
• WFE cycle: management raised its calendar-2026 wafer fab equipment TAM forecast into the low-$150B range, but semi-cap orders are lumpy and any memory or foundry capex digestion hits bookings quickly.
• Advanced packaging: KLA lifted its calendar-2026 advanced packaging process-control outlook to roughly $1.1B, greater than 70% YoY growth, tied to heterogeneous integration - a genuine new growth vector, not a marketing line.
• China export controls and geopolitical restrictions on semicap tool shipments remain a persistent structural tax on the addressable market and a recurring headline risk.
• Rate sensitivity / duration: at 49x trailing earnings and 17.4x sales, KLAC is a long-duration equity - rising real rates or a rotation out of high-multiple AI-adjacent semis compresses the multiple independently of the business.
• Supply chain: management flagged tighter lead times on specific components and slightly elevated input costs, which so far are being absorbed by 40-50% incremental margins but could cap upside if they persist.

• Q1 FY2027 earnings, expected roughly 2026-10-28 to 2026-11-04: guidance of $4.0B revenue (+/- $200M) and $1.16 non-GAAP EPS (+/- $0.10) - the single most important near-term event, and the first real test of the +24.6% YoY acceleration implied by guidance.
• Advanced packaging revenue scaling toward ~$1.1B in calendar 2026 (+70%+ YoY) as heterogeneous integration ramps across leading-edge customers.
• Continued conversion of the >$12B order backlog, with management claiming visibility stretching well into calendar 2027 - a genuine revenue floor if it holds.
• Further WFE TAM upgrades and analyst target revisions (Bernstein recently raised to $250 Outperform; UBS trimmed to $200 Neutral) as the dispersion between $180 and $325 targets resolves.
• A potential multiple re-rating if Q1 FY2027 lands at/above the guidance midpoint and the trailing P/E compresses from 49x toward the high-30s.

• Valuation: 49.0x trailing earnings, 17.4x sales, ~42x EV/EBITDA and a 1.6% FCF yield leave essentially no cushion for a revenue miss, a guidance trim, or a single large customer pushing out capex.
• Cyclicality and estimate risk: consensus FY2027 revenue of $18.1B (+33%) and EPS of $5.488 (+50%) are materially above what the $4.0B Q1 guidance run-rate implies - my own bottom-up estimate is closer to $5.00-5.20 EPS, so the sell-side numbers themselves are a downside vector.
• Cash conversion has not kept pace: TTM FCF of $3.77B was flat YoY (+0.6%) against +11.7% revenue growth, with the Mar-2026 quarter FCF dropping to $622M on working capital - if this is structural rather than a ramp-related build, the FCF-based valuation case weakens.
• Customer concentration in leading-edge foundry/logic and memory means a single capex cut or node delay can move orders meaningfully; the >$12B backlog is only as firm as those customers' capital plans.
• China export controls and any tightening of tool-shipment restrictions would remove a slice of TAM that management's WFE upgrade implicitly assumes stays accessible.
• Insider supply: Form 144 filings and open-market executive sales in August 2026 (including EVP/Chief Legal Officer Mary Beth Wilkinson) add a modest overhang and are a sentiment negative while the stock is already below its 50-day.

KLA is a genuinely elite franchise - 61%+ gross margins, 41.7% TTM operating margin, 35.6% ROIC, dominant process-control share, a >$12B backlog and a guided +24.6% YoY revenue quarter ahead - but at $180.64 on 2026-09-13 you are paying ~35x my FY2027 EPS estimate for a business whose FCF has been flat for a year and whose consensus estimates look 5-10% too optimistic. My own work puts intrinsic value near $172, roughly 5% below the current price, and the tape (below SMA20 and SMA50, RSI 44.8, -29% in three months) offers no tactical entry edge. This is a good business at a full-to-rich price; the honest posture is to wait for the Q1 FY2027 print and a reclaim of the 50-day rather than chase. Not advice - my read of the data.

Method: forward P/E applied to my own FY2027 (June-2027 year-end) EPS estimate, cross-checked against KLA's own multiple history. Inputs: FY2027 revenue of ~$17.5B (built from Q1 guidance of $4.0B plus ~5-7% sequential growth per quarter, below the $18.1B consensus), a ~43% operating margin (vs. 42.5% in the Jun-2026 quarter, using management's 40-50% incremental margin frame), ~85.5% operating-income-to-net-income conversion (the FY26 actual) and ~1.29B shares, giving FY2027E EPS of ~$5.20 versus $5.488 consensus; a 33x multiple, which sits just below KLA's 5-year average trailing P/E of 37.3x and is justified by 61% gross margin, 41.7% operating margin, 35.6% ROIC and a >$12B backlog, but shaded for mid-cycle growth normalisation, flat FCF ($3.77B TTM, +0.6% YoY) and a 1.6% FCF yield. 33 x $5.20 = $171.60, rounded to $172.00 - roughly 5% below the 2026-09-13 price of $180.64 and well below the $225.50 consensus target, reflecting my view that the sell-side EPS base, not just the multiple, carries risk.